Cargando…

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”

Detalles Bibliográficos
Autores principales:	Visentin, Andrea, Trentin, Livio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152985/ https://www.ncbi.nlm.nih.gov/pubmed/34788988 http://dx.doi.org/10.3324/haematol.2021.280199

Ejemplares similares

Response to Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Brown, Jennifer R.
Publicado: (2021)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study
por: Niemann, Carsten U., et al.
Publicado: (2022)

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
por: Takeuchi, Ario, et al.
Publicado: (2020)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Teglgaard, Rebecca, et al.
Publicado: (2023)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Protein Phosphorylation and Redox Status: An as Yet Elusive Dyad in Chronic Lymphocytic Leukemia
por: Pagano, Mario Angelo, et al.
Publicado: (2022)

Comment on Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781
por: van der Pluijm, Rob W., et al.
Publicado: (2022)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
por: Htut, Thura Win, et al.
Publicado: (2021)

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough
por: Cao, Bin, et al.
Publicado: (2020)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
por: Isaac, Krista, et al.
Publicado: (2020)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
por: Ghia, Paolo, et al.
Publicado: (2022)

Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration
por: Oyama, Takashi, et al.
Publicado: (2023)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
por: Lu, Xiaoxiao, et al.
Publicado: (2023)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
por: Quinquenel, Anne, et al.
Publicado: (2023)

Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation
por: Boncompagni, Gioia, et al.
Publicado: (2022)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

Comment
por: Ring, Tim
Publicado: (2020)

Comment
por: Ring, Tim
Publicado: (2020)

Comment
por: Ring, Tim
Publicado: (2021)

COVID-19 vaccination in patients receiving dialysis
por: Wilde, Benjamin, et al.
Publicado: (2021)

When and which patients should receive remdesivir?
por: Garcia-Vidal, Carolina, et al.
Publicado: (2022)

Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?”
por: Di Cesare, Antonella, et al.
Publicado: (2019)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
por: Angotzi, Francesco, et al.
Publicado: (2022)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

Comment on Huang et al. Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis. J. Clin. Med. 2022, 11, 3239
por: Daitch, Vered, et al.
Publicado: (2022)

EDITOR'S COMMENT
por: Vaidya, Rama, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2srpi072ds7uik3af396mg32kj